Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response

Current Opinion in Pharmacology

Volumn 6, Issue 4, 2006, Pages 379-386

  Murray, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CPA 7; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 22; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE SYK; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG SELECTIVITY; ENZYME ACTIVATION; HUMAN; IMMUNOGENICITY; INFLAMMATORY DISEASE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; TOXOPLASMA GONDII;

ANIMALS; ANTINEOPLASTIC AGENTS; DENDRITIC CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-10; MACROPHAGES; NEOPLASMS; RECEPTORS, INTERLEUKIN-10; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TOXOPLASMA; TRANSCRIPTION, GENETIC; VACCINIA VIRUS;

EID: 33745700364     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.01.010     Document Type: Review

References (63)

1. Moore K.W., Vieira P., Fiorentino D.F., Trounstine M.L., Khan T.A., and Mosmann T.R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248 (1990) 1230-1234
2. Fiorentino D.F., Zlotnik A., Vieira P., Mosmann T.R., Howard M., Moore K.W., and O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146 (1991) 3444-3451
3. Bogdan C., Vodovotz Y., and Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 174 (1991) 1549-1555
4. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 (1991) 1209-1220
5. Lang R. Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology 210 (2005) 63-76
6. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
7. Williams L.M., Ricchetti G., Sarma U., Smallie T., and Foxwell B.M. Interleukin-10 suppression of myeloid cell activation - a continuing puzzle. Immunology 113 (2004) 281-292
8. Donnelly R.P., Dickensheets H., and Finbloom D.S. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19 (1999) 563-573
9. O'Garra A., Vieira P.L., Vieira P., and Goldfeld A.E. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 114 (2004) 1372-1378
10. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., and Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16 (2002) 219-230
11. Roers A., Siewe L., Strittmatter E., Deckert M., Schluter D., Stenzel W., Gruber A.D., Krieg T., Rajewsky K., and Muller W. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med 200 (2004) 1289-1297. This elegant study uses a T cell-specific knockout of IL-10 to show that IL-10 from T cells is primarily required to control chronic inflammation, whereas IL-10 from other sources (suspected to be macrophages and dendritic cells) is required to dampen the inflammatory response in acute inflammation.
12. Park J.M., Greten F.R., Wong A., Westrick R.J., Arthur J.S., Otsu K., Hoffmann A., Montminy M., and Karin M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis - CREB and NF-kappaB as key regulators. Immunity 23 (2005) 319-329
13. Dillon S., Agrawal A., Van Dyke T., Landreth G., McCauley L., Koh A., Maliszewski C., Akira S., and Pulendran B. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 172 (2004) 4733-4743
14. Rogers N.C., Slack E.C., Edwards A.D., Nolte M.A., Schulz O., Schweighoffer E., Williams D.L., Gordon S., Tybulewicz V.L., Brown G.D., et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22 (2005) 507-517
15. Gazzinelli R.T., Wysocka M., Hieny S., Scharton-Kersten T., Cheever A., Kuhn R., Muller W., Trinchieri G., and Sher A. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 157 (1996) 798-805
16. Hunter C.A., Ellis-Neyes L.A., Slifer T., Kanaly S., Grunig G., Fort M., Rennick D., and Araujo F.G. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J Immunol 158 (1997) 3311-3316
17. Berg D.J., Kuhn R., Rajewsky K., Muller W., Menon S., Davidson N., Grunig G., and Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 96 (1995) 2339-2347
18. Howard M., Muchamuel T., and Andrade S. Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177 (1993) 1205-1208
19. Lang R., Rutschman R.L., Greaves D.R., and Murray P.J. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol 168 (2002) 3402-3411
20. Kuhn R., Lohler J., Rennick D., Rajewsky K., and Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
21. North R.J. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 113 (1998) 55-58
22. Murray P.J., Wang L., Onufryk C., Tepper R.I., and Young R.A. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 158 (1997) 315-321
23. Turner J., Gonzalez-Juarrero M., Ellis D.L., Basaraba R.J., Kipnis A., Orme I.M., and Cooper A.M. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 169 (2002) 6343-6351
24. Hoffmann K.F., Cheever A.W., and Wynn T.A. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 164 (2000) 6406-6416
25. Hoffmann K.F., James S.L., Cheever A.W., and Wynn T.A. Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni. J Immunol 163 (1999) 927-938
26. Specht S., Volkmann L., Wynn T., and Hoerauf A. Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. Infect Immun 72 (2004) 6287-6293
27. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., and Sacks D.L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420 (2002) 502-507
28. Riley J.K., Takeda K., Akira S., and Schreiber R.D. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 274 (1999) 16513-16521
29. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., King K.L., Sheehan K.C., Yin L., Pennica D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93 (1998) 373-383
30. Weber-Nordt R.M., Riley J.K., Greenlund A.C., Moore K.W., Darnell J.E., and Schreiber R.D. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem 271 (1996) 27954-27961
31. Lang R., Patel D., Morris J.J., Rutschman R.L., and Murray P.J. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 169 (2002) 2253-2263
32. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., and Akira S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10 (1999) 39-49
33. Williams L., Bradley L., Smith A., and Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 172 (2004) 567-576
34. Alexander W.S., and Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22 (2004) 503-529
35. Williams L., Jarai G., Smith A., and Finan P. IL-10 expression profiling in human monocytes. J Leukoc Biol 72 (2002) 800-809
36. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4 (2003) 540-545
37. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., Rutschman R., and Murray P.J. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4 (2003) 546-550
38. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., Silva A., Asimakis M., Farley A., Nash A.D., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97 (2000) 6493-6498
39. De Souza D., Fabri L.J., Nash A., Hilton D.J., Nicola N.A., and Baca M. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41 (2002) 9229-9236
40. Lehmann U., Schmitz J., Weissenbach M., Sobota R.M., Hortner M., Friederichs K., Behrmann I., Tsiaris W., Sasaki A., Schneider-Mergener J., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 278 (2003) 661-671
41. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., and Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275 (2000) 12848-12856
42. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., Hanada T., Takeda K., Akira S., Hoshijima M., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4 (2003) 551-556
43. Murray P.J. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci USA 102 (2005) 8686-8691. Genetic and biochemical demonstration that IL-10 controls inflammatory gene expression at the transcriptional level via a pathway that requires the synthesis of new proteins, confirming long-held suspicions regarding the IL-10 mechanism of targeting transcription by an indirect mechanism (see also [3,4]).
44. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707-721. The authors show that dexamethasone selectively inhibits inflammatory gene expression at the transcriptional level via two mechanisms involving nuclear hormone-activated trans-repression.
45. Pranada A.L., Metz S., Herrmann A., Heinrich P.C., and Muller-Newen G. Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem 279 (2004) 15114-15123
46. Zhou L., Nazarian A.A., and Smale S.T. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 24 (2004) 2385-2396
47. Donnelly R.P., Sheikh F., Kotenko S.V., and Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 76 (2004) 314-321
48. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., and Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174 (2005) 3695-3702
49. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., and Sabat R. IL-22 increases the innate immunity of tissues. Immunity 21 (2004) 241-254
50. Radaeva S., Sun R., Pan H.N., Hong F., and Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39 (2004) 1332-1342
51. Hamano S., Himeno K., Miyazaki Y., Ishii K., Yamanaka A., Takeda A., Zhang M., Hisaeda H., Mak T.W., Yoshimura A., et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19 (2003) 657-667
52. Miyazaki Y., Inoue H., Matsumura M., Matsumoto K., Nakano T., Tsuda M., Hamano S., Yoshimura A., and Yoshida H. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol 175 (2005) 2401-2407
53. Yamanaka A., Hamano S., Miyazaki Y., Ishii K., Takeda A., Mak T.W., Himeno K., Yoshimura A., and Yoshida H. Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis. J Immunol 172 (2004) 3590-3596
54. Holscher C., Holscher A., Ruckerl D., Yoshimoto T., Yoshida H., Mak T., Saris C., and Ehlers S. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 174 (2005) 3534-3544
55. Villarino A.V., Stumhofer J.S., Saris C.J., Kastelein R.A., de Sauvage F.J., and Hunter C.A. IL-27 limits IL-2 production during Th1 differentiation. J Immunol 176 (2006) 237-247
56. Kano A., Wolfgang M.J., Gao Q., Jacoby J., Chai G.X., Hansen W., Iwamoto Y., Pober J.S., Flavell R.A., and Fu X.Y. Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J Exp Med 198 (2003) 1517-1525
57. Levy D.E., and Lee C.K. What does Stat3 do?. J Clin Invest 109 (2002) 1143-1148
58. •].
59. •].
60. •] show that STAT3 plays a key role in the ability of the body to recognize and respond to tumors.
61. Coombes B.K., Valdez Y., and Finlay B.B. Evasive maneuvers by secreted bacterial proteins to avoid innate immune responses. Curr Biol 14 (2004) R856-R867
62. Butcher B.A., Kim L., Panopoulos A.D., Watowich S.S., Murray P.J., and Denkers E.Y. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-alpha in host macrophages. J Immunol 174 (2005) 3148-3152. The pathogenic parasite is shown to directly activate the STAT3-dependent anti-inflammatory pathway to inhibit macrophage activation.
63. Maloney G., Schroder M., and Bowie A.G. Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J Biol Chem 280 (2005) 30838-30844